TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.

The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design,” has been accepted as a late-breaking poster presentation (Presentation Number: Sun-522) during Late Breaking Poster Session II on Sunday, October 11, 2026. Led by Dr. Felicia Cosman, Professor of Medicine at Columbia University and an internationally recognized osteoporosis authority, the presentation will outline the study design and clinical methodology for Entera’s planned single, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating EB613 in postmenopausal women with osteoporosis.

This presentation is in addition to the Company’s Phase 2 clinical data for EB613 which was selected for a Plenary Poster presentation at the meeting, evaluating treatment effects in postmenopausal women with osteopetrosis at high risk of fracture.

Presentation Details:

Abstract Title: EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design

Session Title: Late Breaking Poster Session II
Presentation Number: Sun-522
Session Date/Time: Sunday, October 11, 2026, 2:00-3:30 p.m. ET

Abstract Title: EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial

Session Title: Welcome Reception and Plenary Poster Session (Plenary Poster Presentation)
Presentation Number: Fri-026
Session Date/Time: Friday, October 9, 2026, 5:30-7:00 p.m. ET

Session Title: Poster Session II
Presentation Number: Sun-026
Session Date/Time: Sunday, October 11, 2026, 2:00-3:30 p.m. ET

About EB613
Substantial evidence supports the efficacy of anabolic therapies over anti-resorptive agents for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. Entera’s EB613 program (oral PTH(1-34), teriparatide) is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Entera completed a Phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D-DXA showed increases with EB613 compared to placebo on a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with that of published subcutaneous teriparatide at the 6-month time point.

About Entera
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Company Contact:
IR@enterabio.com

  • Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis

FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.

Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA® (vonoprazan) in Gastroesophageal Reflux Disease (GERD), including a post hoc analysis of VOQUEZNA efficacy in patients with Non-Erosive GERD across Body Mass Index (BMI) subgroups, a retrospective analysis of real-world patient characteristics, and a model examining the cost-effectiveness of VOQUEZNA compared with proton pump inhibitors (PPIs) in Erosive Esophagitis, or Erosive GERD. The Company will also host a Product Theater to highlight the clinical efficacy and safety profile of VOQUEZNA.

“ACG provides an important opportunity to continue advancing the scientific dialogue around GERD and share new insights with the GI community,” said Steve Basta, President and Chief Executive Officer of Phathom. “These analyses add to the growing body of data on VOQUEZNA and provide new perspectives relevant to its use in GERD. We look forward to discussing these findings with GI healthcare providers and hearing firsthand perspectives from clinicians and patients throughout the meeting.”

Phathom’s Presentations at ACG 2026:

Sunday, October 11, 2026

  • Vonoprazan Efficacy Across BMI Subgroups in Non-Erosive Reflux Disease
    • Poster: P0624
    • Time: 3:30 PM – 7:00 PM CDT
    • Presenter: Catiele Antunes, MD, Assistant Professor of Medicine and Director of the Refractory GERD Clinic at Yale School of Medicine

Monday, October 12, 2026

  • Characteristics of US Patients With Gastroesophageal Reflux Disease (GERD) Taking Vonoprazan or a Prescription Proton Pump Inhibitor (PPI)
    • Poster: P2921
    • Time: 10:30 AM – 4:15 PM CDT
    • Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine
  • VOQUEZNA® (vonoprazan) Product Theater: Beyond the Data: From Clinical Cases to Patient Perspectives
    • Location: Booth #117 – ACG Product Theater
    • Time: 3:45 PM CDT
    • Presenters: John E. Pandolfino, MD, MSCI, Chief of Gastroenterology and Hepatology and Hans Popper Professor of Medicine at Northwestern University Feinberg School of Medicine; and a Patient Speaker

Tuesday, October 13, 2026

  • Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes
    • Poster: P5160
    • Time: 10:30 AM – 4:00 PM CDT
    • Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine

Attendees can also visit Phathom’s Medical Affairs and Commercial teams on the exhibit floor at Booth 323.

About VOQUEZNA
INDICATIONS AND USAGE
VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:

  • for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD.
  • to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD.
  • for the relief of heartburn associated with Non-Erosive GERD.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.

WARNINGS AND PRECAUTIONS

Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.

Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.

Clostridioides difficile-Associated Diarrhea: Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

Bone Fracture: Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.

Severe Cutaneous Adverse Reactions (SCAR): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.

Vitamin B12 (Cobalamin) Deficiency: Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.

Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.

Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.

Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.

Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high.

Fundic Gland Polyps: Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

ADVERSE REACTIONS

Healing of Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).

Maintenance of Healed Erosive GERD: The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).

Relief of Heartburn Associated with Non-Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%).

DRUG INTERACTIONS

VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/.

Lactation: There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition.

Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min).

Hepatic Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C).

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information for VOQUEZNA.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding Phathom’s planned participation in and presentations at the ACG 2026 Annual Scientific Meeting. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such statements, including risks and uncertainties associated with the Company’s business described under the heading “Risk Factors” in Phathom’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by Phathom’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release, and Phathom undertakes no obligation to update such statements, except as required by law.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

09/26 US-VPZ-26-0310

By lowering the engineering effort between an idea and the hardware, the new feature enables faster experimentation while keeping scientists in control

PARIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Pasqal (Nasdaq: PSQL), a global leader in neutral-atom quantum computing, today announced the availability of an AI-assisted workflow on Pasqal Cloud. Available as a plugin for leading agentic coding environments, the new feature can take a well-defined scientific idea to a running experiment on a quantum processing unit (QPU), significantly reducing the engineering effort that has long stood between an idea for a quantum use case and its execution on hardware.

As quantum computers become easier to access through the cloud, the challenge is shifting from hardware availability to how researchers design, run and interpret quantum experiments. Translating a protocol into a hardware-ready job still requires specialized engineering expertise and significant time. As a result, many promising ideas go untested, even when suitable hardware exists.

The AI-assisted workflow orchestrates the full pipeline. Starting from an experiment described in a paper or conceived as an original idea, it extracts or formalizes the protocol, translates it into a hardware-ready quantum job, validates it in emulation, submits it through the cloud and processes the results into scientific observables.

“The bottleneck in quantum computing is shifting,” said Wasiq Bokhari, CEO of Pasqal. “The engineering work that once demanded a researcher’s attention can increasingly be automated, allowing researchers to focus more fully on the science. Our QPUs are deployed and accessible in the cloud today. With this AI-assisted workflow lowering the barrier to using them, we are making quantum computing power available to a much broader community.”

Rather than replacing scientists, the workflow is designed to keep scientific judgment at the center. It coordinates the engineering and removes friction, while ideation, validation and decisions about what to measure and whether a result genuinely supports a physical claim, remain with the users.

The AI-assisted workflow can be installed as a plugin in leading agentic coding environments, including Claude Code, Cursor, Codex and others. Experiments can then be run on three Pasqal Cloud QPUs available to external users: Ruby, operated by GENCI at CEA, located in France, FC1, located in Sherbrooke (Québec, Canada) and SA1, located in the Kingdom of Saudi Arabia.

To learn more about the AI-assisted workflow, read our blog post, “Turning Ideas into QPU Experiments: How Agentic Workflows Make Quantum Computing More Accessible,” for a full technical deep dive, or visit the documentation.

Contacts

Investors
investors@pasqal.com 

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future. 

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network). 

Forward-Looking Statements
Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project”, “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s ability to accelerate global deployment of its quantum computing platform.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.

Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the “Investors” section of Enovis’ website at www.enovis.com.

Conference Call/Webcast Information

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A link to a replay of the call will also be available on the Enovis website later that day.

About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.

Availability of Information on the Enovis Website

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.

Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com

Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development. The Company has advanced its transformation into a precision oncology-led biotechnology company, with a portfolio of select novel assets, anchored by CD228V, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, SkinJect for basal cell carcinomas in patients with Gorlin syndrome and Teverelix for development opportunities in urology and women’s health.

This transformation, outlined in our recent strategic update, reflects progress in clinical advancement, strategic acquisitions, and investment in the people and capabilities needed to execute. From a company centered on SkinJect, we have built a portfolio with multiple potential paths to clinical and commercial value.

Our progress has occurred alongside stock-price volatility and pullback. We must make a concerted effort to explain more clearly, when we can, how the investments made to date position Medicus and support that explanation with measurable results.

Building the Foundation for Potential Long-Term Value

Our strategy is to identify promising therapeutic assets with existing scientific and clinical foundations and concentrate incremental investment on milestones that can strengthen their development prospects and partnering value.

Over these three years, we have assembled a board and management team and established the clinical, regulatory, financial, and governance capabilities needed to advance our programs. Commencing in October 2023, our progression from the TSX Venture Exchange to Nasdaq in November 2024, broadened our access to public capital markets. Approximately $90 million raised through equity and debt financing supported clinical development, strategic acquisitions, and organizational operations, while retaining resources for ongoing requirements.

That investment has given Medicus a broader portfolio and the capacity to pursue more complex development opportunities. Its ultimate return will depend on the clinical evidence we generate, the partnerships we secure, and the discipline with which we manage future spending.

CD228V and the Opportunity in Targeted Cancer Therapy

Antibody-drug conjugates, or ADCs, combine an antibody that recognizes a target on cancer cells with a potent cancer-killing payload. Their promise lies in directing treatment toward tumor cells, although the balance between antitumor activity and toxicity depends on the target, molecular design, and clinical setting.

CD228V brings together a less crowded solid-tumor target, second-generation molecular engineering, and an existing clinical and manufacturing foundation. It targets melanotransferrin, also known as CD228, a cell-surface protein associated with melanoma and expressed across several other solid tumors. Its expression and potential for internalization make it an attractive target for delivering an ADC payload.

Our initial priority is melanoma, particularly relapsed, refractory, or immunotherapy-resistant disease, where additional treatment options are needed. We intend to integrate biomarker work into development to better understand which patients may benefit.

We believe CD228V also has potential beyond melanoma, including in CD228-expressing lung, head and neck, and esophageal cancers. CD228V is early in development, and neither its efficacy nor an improved safety profile has been established; no approved therapy has yet validated CD228 as a treatment target.

We believe the combination of target biology, molecular design, and development readiness gives CD228V a compelling place in our portfolio. Our goal is to translate that foundation into evidence that can support further development and attract partners with complementary capabilities.

SkinJect and a Focused Gorlin Syndrome Strategy

We completed the SKNJCT-003 Phase 2 study, evaluated its findings, and identified the 200-microgram dose for further development. The FDA subsequently authorized initiation of SKNJCT-005, our planned registrational study in patients with Gorlin syndrome, an autosomal dominant rare disease.

Patients with Gorlin syndrome face a lifetime burden of recurrent basal cell carcinomas and repeated procedures. We believe this population provides a focused setting in which to evaluate SkinJect as a localized treatment option.

The completed work has informed dose selection and defined the next study, providing a clearer basis for allocating resources and evaluating potential partnerships. Additional clinical evidence and regulatory review remain necessary.

Teverelix and Partner Ready Development Opportunities

The acquisition of Antev in August 2025 expanded our portfolio into urology and women’s health through Teverelix, an investigational, next generation, GnRH antagonist. We subsequently strengthened its underlying economics by reducing the royalty rate and refined its priorities to acute urinary retention relapse prevention and symptomatic endometriosis, alongside a partnership-led strategy in advanced prostate cancer patients with high cardiovascular risk profile.

Our recent submission of an optimized registrational protocol for advanced prostate cancer is intended to incorporate previously FDA-cleared dose-optimization work into a proposed integrated development program. Subject to FDA review, this approach is designed to give potential partners a clearer plan for advancing the asset.

The Next Phase of Execution

Our priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing, co-development, and other strategic opportunities. Partnerships could contribute non-dilutive development funding and expertise while reducing the capital Medicus would otherwise need to provide. Their timing, terms, and completion remain uncertain.

For our shareholders, we continue to strive to help make the connection between our portfolio and potential value more tangible. We are committed to explain the significance of each milestone, the resources required to reach it, and the decisions it enables. The measure of our progress should be stronger clinical evidence, clearer development pathways, and transactions that support continued advancement.

We remain confident in the purpose of our work and committed to responsible capital allocation. We have built a company with a broader scientific opportunity than when we began. Our mission is to demonstrate what that opportunity can deliver for patients and shareholders.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations 
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the planned initiation, timing, design, conduct and results of the SKNJCT-005 registrational study in patients with Gorlin Syndrome, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer, women’s health indications like endometriosis, the FDA’s feedback regarding the Company’s Phase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed design of the Phase 2b/3 registration-intent program, the potential to reduce the overall planned APC clinical development program from approximately 1,500 patients to approximately 600 patients, the establishment of a defined, capital-efficient and partner-ready registrational pathway for Teverelix® without Medicus independently funding an additional APC clinical development study, Medicus’ intent and ability to out-license or otherwise strategically partner the Teverelix® APC program, the anticipated completion of GMP-grade manufacturing, quality-release and other clinical study readiness steps before the end of 2026, whether the proposed cardiovascular-focused registrational strategy, including the 12-month non-calcified coronary plaque endpoint assessed using non-invasive coronary CCTA and the evaluation of Teverelix® effects on APC patients at increased cardiovascular risk, could support registration, the Company’s capital-efficient portfolio strategy and the anticipated benefits thereof, the Company’s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “goal”, “strive”, “intended”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Joint offering combines XBP’s Smart Office suite, CXAI’s employee experience platform, and Macro Group’s facilities management expertise; showcased at “The Future of Work” event in New York

IRVING, Texas, Oct. 08, 2026 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company powering intelligent workflows for organizations worldwide, today announced a collaboration with CXApp Inc. (NASDAQ: CXAI) (“CXAI”) and Macro Group to deliver an integrated, technology-enabled hybrid workplace offering for enterprise clients.

The three companies presented the joint offering on October 7, 2026 at “The Future of Work,” an event hosted at XBP Global’s office in New York.

Connected workplace offering

Hybrid work has left many organizations with scattered mail, manual handoffs between teams, and office space that is used unevenly. The joint offering addresses these issues by connecting physical workplace operations with employee-facing technology and facilities management.

Each company contributes a distinct layer:

  • XBP Global’s Smart Office suite unifies inbound receiving, outbound shipping, digital mail, and facility services on one connected platform. XBPTrack provides single-scan chain-of-custody tracking for inbound physical mail and packages, with real-time recipient notifications and smart locker integration. Complementing physical processing, digital mail solutions digitize incoming correspondence at the point of receipt, extracting actionable data and embedding digital documents directly into client downstream platforms—such as ERP, CRM, and ECM systems—to fuel automated enterprise workflows. XBPShip lets users compare carrier rates, generate labels, and ship from a desk or mobile device, with built-in address validation and compliance screening. XBPH360 replaces informal facility checklists with digital logs, timestamps, and photo validation.
  • CXAI’s employee and workplace experience platform, Flow, serves as an agentic AI layer for the hybrid enterprise, consolidating disconnected workplace tools into one seamless platform to deliver a frictionless workday. Employees can effortlessly book spaces, navigate campuses, manage and announce internal events, access smart lockers, and handle workplace services, including food ordering, service ticketing, and more, all in one place. Its natural-language AI companion completes everyday tasks on demand via voice or text, while providing workplace and real estate leaders with predictive recommendations to ensure spaces are better used, streamline services, and continuously optimize enterprise operations.
  • Macro Group provides facilities management and health, safety and environment (HSE) consultancy, aligning clients’ physical spaces with their hybrid work strategies.

The result: self-service for employees and real-time visibility for facility and real estate teams.

“Our clients rely on us to embed technology directly into their mission-critical workflows—transforming physical workplaces, modernizing digital mail platforms, and stripping friction out of everyday operations,” said Andrej Jonovic, Chief Executive Officer of XBP Global. “Hybrid work has made workplace management far more complex. Bringing our Smart Office suite together with CXAI’s employee experience platform and Macro Group’s facilities expertise gives clients one connected, real-time view of their workplace operations.”

Interested organizations can learn more and request a demonstration at lp.xbpglobal.com/the-future-of-work.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These statements include financial forecasts, projections, and other statements about future operations, financial position, business strategy, market opportunities, and trends. Forward-looking statements can often be identified by terms such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast,” or similar expressions. All forward-looking statements are based on estimates, forecasts, and assumptions that are inherently uncertain and subject to risks and factors that could cause actual results to differ materially. These include, but are not limited to: (1) risks related to the acquisition and related restructuring, including the inability to realize anticipated benefits, disruptions to operations, and costs associated with the acquisition; (2) legal proceedings; (3) failure to maintain compliance with Nasdaq listing standards; (4) competition and market conditions; (5) economic, geopolitical, and regulatory changes; (6) challenges in retaining clients, employees, and suppliers; and (7) other risks detailed in the Company’s filings with the SEC, including the “Risk Factors” section of its Annual Report on Form 10-K for 2025. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. XBP Global undertakes no obligation to update these statements, except as required by law. There is no assurance that XBP Global or its subsidiaries will achieve the results projected in these statements.
     
About XBP Global

XBP Global is a multinational technology and services company powering intelligent workflows for organizations worldwide. With a presence in 20 countries and approximately 9,200 employees, XBP Global partners with over 2,000 clients, including many of the Fortune 100, to orchestrate mission-critical systems that enable hyper-automation.

Our proprietary platforms, agentic AI-driven automation, and deep domain expertise across industries and the public and private sectors enable our clients to entrust us with their most impactful digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine how they work, transact, and unlock value.

About CXAI

CXAI is an enterprise agentic AI platform company focused on helping organizations improve productivity, automate workflows and enhance business performance through artificial intelligence.

CXAI’s platform combines operational intelligence, analytics, workplace technologies and intelligent automation to deliver measurable business outcomes across enterprise and mid-market organizations. CXAI serves customers across technology, financial services, healthcare, media and other industries while expanding its AI capabilities through both organic growth and strategic acquisitions.

About Macro Group

Macro Group is a global facilities management delivery company providing high-performing, experience-led environments for complex real estate portfolios.

Operating in over 45 countries, we deliver integrated facilities management services alongside project consultancy and HSE advisory expertise, helping organizations optimize performance, enhance workplace experiences, manage risk and ensure compliance across the built environment.

For more news, commentary, and industry perspectives, visit: https://www.xbpglobal.com/ 

And please follow us on social:

X: https://X.com/XBPglobal

LinkedIn: https://www.linkedin.com/company/xbpglobal/ 

The information posted on XBP Global’s website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in XBP Global should monitor XBP Global’s website and its social media accounts in addition to XBP Global’s press releases, SEC filings and public conference calls and webcasts.

CONTACT: Investor Relations: investors@xbpglobal.com | Media Queries: press@xbpglobal.com

Proposed acquisition adds a road-accessible porphyry exploration project approximately 90 kilometres south-southwest of Houston, British Columbia

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) is pleased to announce that it has entered into a purchase agreement dated October 7, 2026 (the “Agreement”) with Orogen Royalties Inc. (“Orogen”) to acquire from Orogen a 100% interest in the Cibola copper-gold project (“Cibola” or the “Property”) in British Columbia, subject to a 2% net smelter returns royalty and the obligations described below (the “Acquisition”).

Cibola comprises approximately 3,567 hectares of road-accessible mineral claims approximately 90 kilometres south-southwest of Houston, British Columbia. The Property lies in a region hosting porphyry copper-molybdenum deposits associated with the Bulkley and Babine intrusive suites, including the past-producing Huckleberry Mine. Mineralization at nearby properties is not necessarily indicative of mineralization at Cibola.

Cibola Project location and claim boundary, showing road access and the approximate locations of the Main and Gold zones

Figure 1. Cibola Project location and claim boundary, showing road access and the approximate locations of the Main and Gold zones.

Previous exploration identified two exposed areas known as the Main Zone and Gold Zone within a property largely covered by glacial deposits. Historical geological and geophysical work identified extensive alteration and an approximately 2.0-kilometre by 1.4-kilometre induced polarization (“IP”) chargeability anomaly exceeding 40 mV/V at the Main Zone. These dimensions describe the geophysical anomaly, rather than a defined mineralized body. Subsequent IP work in 2019 and airborne electromagnetic and magnetic surveys in 2025 provided additional information supporting the porphyry exploration model. Orogen’s interpretation identifies conductivity and magnetic anomalies overlapping the IP chargeability anomaly, anomalous surface geochemistry and areas of historical shallow drilling. Together, these results support the interpretation of a potential copper-gold-molybdenum porphyry system.

The geological model interprets the combined information as potentially reflecting intrusive bodies beneath an alteration blanket. Historical percussion drilling at the Main Zone was predominantly shallow (average hole length approximately 60 metres) and intersected several anomalous intervals. Orogen considers the interpreted deeper porphyry target insufficiently tested. This interpretation provides a basis for further exploration; it does not establish the presence of an economic mineral deposit.

“Cibola broadens our exploration portfolio with a road-accessible copper-gold-molybdenum target supported by several generations of geological and geophysical work,” said Jared Suchan, Ph.D., P.Geo., Chief Executive Officer and Director of Northern Discovery. “Our priority is to integrate the existing information and refine the geological interpretation so that subsequent exploration can test the target systematically.”

Under the Agreement, the Company will pay $130,000 and issue 700,000 common shares (“Shares”) to Orogen as follows:

  • $30,000 and 100,000 Shares at closing;
  • $50,000 and 300,000 Shares on the earlier of receipt of a drilling permit for the Property and July 31, 2027; and
  • $50,000 and 300,000 Shares on the earlier of six months after receipt of a drilling permit for the Property and December 31, 2027.

All amounts are in Canadian dollars. Shares will be subject to a statutory hold period of four months and one day from issuance. The Acquisition is arm’s length, and no finder’s fees are payable.

At closing, the Company will grant Orogen or its nominees a 2% net smelter returns royalty on the Property, reducible to 1.5% by written notice and payment of $5,000,000 no later than 90 days after completion of the earlier of: a pre-feasibility; or a feasibility study. The royalty also applies to additional mineral interests acquired within a one-kilometre area of interest, as provided in the royalty agreement.

If the Company has not completed 15,000 metres of drilling on the Property by August 12, 2030, annual payments of $20,000 to the underlying optionors will commence and continue until that threshold is met.

Completion of the Acquisition is subject to CSE approval and satisfaction or waiver of the other closing conditions in the Agreement. Closing is expected to occur two business days after those conditions are satisfied or waived, or on another date agreed by the parties. There can be no assurance that the Acquisition will be completed on the anticipated terms or timeline.

Qualified Person Statement

Jared Suchan, Ph.D., P.Geo. (EGBC #67668), Chief Executive Officer and Director of the Company, and a “Qualified Person” within the meaning of National Instrument 43-101 — Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical contents of this news release.

The technical discussion of Cibola is based on Dr. Suchan’s review of the existing technical information relating to the Property, including the exploration information and geological interpretations summarized by Orogen. Dr. Suchan’s data verification was limited to reviewing the available technical records. No new sampling or assay results, mineral resource estimates or mineral reserve estimates are reported in this release. Historical interpretations remain subject to confirmation through further exploration, and geophysical anomalies may have causes unrelated to economic mineralization. For a further discussion of the Company’s QA/QC and data verification processes and procedures, please see its most recently-filed technical report, a copy of which may be obtained under the Company’s profile at www.sedarplus.ca.

About Northern Discovery Metals Inc.

Northern Discovery Metals Inc. is a mineral exploration company focused on the acquisition, exploration and advancement of mineral properties in Canada. The Company is exploring for copper at its Vent Project on Vancouver Island, British Columbia, where it holds an option to acquire a 100% interest. Northern Discovery has also entered into an agreement to acquire the Cibola copper-gold project in British Columbia, subject to the closing conditions described in this release.

On Behalf of the Board of Directors

Dr. Jared Suchan
Chief Executive Officer and Director

Phone: (604) 294-3020
Email: info@northerndiscoverymetals.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws. These statements include statements concerning completion and timing of the Acquisition; satisfaction of closing conditions and receipt of CSE approval; future cash payments, share issuances and royalty obligations; the potential exercise of the royalty reduction right; receipt of drilling permits; the geological interpretation and exploration potential of Cibola; and the Company’s plans to evaluate and advance the Property.

Forward-looking statements are based on management’s current expectations and assumptions, including that the parties will perform their contractual obligations; required approvals and permits will be obtained; sufficient financing, personnel and contractors will be available; existing technical information will provide a reasonable basis for further evaluation; and access arrangements, field conditions and regulatory requirements will permit the contemplated activities.

Actual results may differ materially because of risks including failure to complete the Acquisition or obtain required approvals; financing constraints; permitting or access delays; uncertainties concerning mineral title and assumed liabilities; environmental and reclamation obligations; incomplete or unreliable historical information; changes in geological interpretations; unsuccessful exploration; adverse field conditions; increased costs; and changes in commodity prices, capital markets or government requirements. Exploration may not identify an economic mineral deposit. Additional risks are described in the Company’s continuous disclosure filings available on SEDAR+.

There can be no assurance that the Acquisition will close or that proposed exploration will proceed or achieve the anticipated results. Readers are cautioned against placing undue reliance on forward-looking statements, which speak as of the date of this release. The Company undertakes no obligation to update these statements except as required by applicable securities laws.

The CSE has neither approved nor disapproved the information contained herein.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2fe2b56c-ee78-4ded-b393-ca364f079641

Program advances to data interpretation to help prioritize ground EM follow-up on the AS-1 target area

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company“) is pleased to announce the completion of fieldwork for the ambient noise tomography (“ANT”) survey at the Astro Project (“Astro” or the “Project”) in the eastern Athabasca Basin, Saskatchewan. Seismic sensors have been recovered, and the program has advanced to data processing and interpretation to support the next phase of exploration. CAUR Technologies (“CAUR”) completed the fieldwork, with Cosa Resources Corp. (“Cosa”) serving as Project operator. The program included 21 days of seismic monitoring, completed in July, followed by sensor retrieval. The work is intended to help Global and Cosa prioritize areas for follow-up ground electromagnetic (“EM”) surveying and future drill targeting.

The ANT survey focused on the AS-1 target area, which covers a substantial portion of the approximately 25-kilometre-long, east-northeast-trending conductive corridor identified by the 2025 airborne ZTEM survey. ANT uses recordings of ambient seismic noise to develop models of subsurface shear-wave velocity. These models can help refine interpretations of rock units, structural features and potential alteration within the lower Athabasca sandstone and upper basement rocks. The ANT interpretation will be assessed alongside the existing Z-Axis Tipper Electromagnetic (“ZTEM”) dataset to select priority areas for proposed ground EM surveying during the upcoming winter field season. Ground EM would provide additional definition of conductive targets ahead of potential drilling. The scope and timing of follow-up work remain subject to the completed ANT interpretation, contractor availability, funding and required approvals.

“Completing the fieldwork moves Astro into the next stage of evaluation,” said Ungad Chadda, CEO of Global Uranium. “We are focused on using the ANT results alongside the existing airborne geophysics to prioritize follow-up work and build toward well-supported drill targets.”

Global expects to provide a further update following completion and review of the ANT interpretation. Geophysical anomalies are exploration targets and do not, on their own, establish the presence of uranium mineralization.

QUALIFIED PERSON

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., a Qualified Person as defined by NI 43-101″.

ABOUT GLOBAL URANIUM CORP.

Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Project in the Mudjatik Domain of northern Saskatchewan, Canada; the Astro Project (with Cosa Resources Corp.) in the eastern Athabasca Basin, Saskatchewan; the Airline Project in the northern Wind River Basin, Wyoming, USA; as well as additional projects across the Gas Hills and Great Divide Districts in Wyoming.

ON BEHALF OF THE BOARD OF DIRECTORS

Ungad Chadda
CEO

587-330-0045
info@globaluranium.com

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.

In particular, this press release contains forward-looking information relating to, among other things: the Project, including the prospectivity of the Project, its potential to host extensions of the McArthur River/Fox Lake Structural Corridor and other beneficial geological trends; and the Company’s and Cosa’s exploration plans with respect to the Project, including the Project’s candidacy for advanced geophysical exploration and drilling to delineate compelling targets. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that: the historical work done with respect to the Project is representative of the actual geological nature of the Project; that the Project may share the geological characteristics of nearby projects, deposits and mines; and that the Company and Cosa will successfully collaborate with respect to the exploration of the Project pursuant to the Option Agreement, including by progressing advanced geophysical exploration and drilling. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include: the risk that the Company does not earn-in to any interest in the Project pursuant to the Option Agreement; risks inherent in the Company and Cosa’s joint exploration of the Project, including the risk that the Company and Cosa disagree on the manner or timeline for the exploration of the Project and/or are unable to collaborate on the exploration of the Project successfully pursuant to the Option Agreement; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company; that the characteristics of the Project may not reflect the characteristics of nearby projects, deposits and mines; operational risks; regulatory risks, including risks relating to the CSE’s approval of the share issuances pursuant to the Option Agreement and the acquisition of the necessary licenses and permits to conduct exploration on the Project; financing, capitalization and liquidity risks; title and environmental risks; and risks relating to the failure to receive all requisite regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this ‎press release.‎

ANDOVER, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today reported select financial results for its fiscal third quarter (“Q3 2026”) ended August 31, 2026.

Fiscal Third Quarter 2026 and Recent Operational Highlights

  • Completed the acquisition of HERO Defense Systems, LLC, a complementary less-lethal self-defense company, expanding Byrna’s product portfolio into additional price points and form factors.
  • Onboarded more than 50 influencers with a combined following of 3.8 million people through Acceleration Partners as part of a broader initiative to build the Company’s growing social creator ecosystem and expand brand awareness on new platforms.
  • Reallocated marketing investments within iHeartMedia toward a partnership with The Bobby Bones Show, expanding Byrna’s reach to mainstream consumer audiences while increasing national brand awareness.
  • Launched and sold through all available refurbished product inventory, driving incremental earnings during the period and providing a longer-term revenue diversification channel.
  • Successfully transitioned ammunition production to an outsourced model, improving ammunition gross margins by approximately 1,200 basis points in the quarter and reducing operational complexity to drive greater overall profitability.
  • Continued executing operational efficiency initiatives and product mix optimization efforts, contributing to gross margin expansion from 60% to 79% year-over-year, reflecting a one-time $2.3 million tariff refund; excluding that item, adjusted gross margin, a non-GAAP measure, improved to approximately 65%.
  • Strengthened leadership team with the additions of Jim White, Senior Vice President of Retail & Channel Growth, and Nate Secor, Senior Vice President of Brand and Marketing, to accelerate retail expansion, omnichannel growth, customer acquisition, and brand development.
  • Appointed Rose Lopez Keravuori and Dr. Matthew McBrady to the Board of Directors, bringing additional expertise in enterprise risk management, capital markets, corporate governance, and scaling growth-oriented organizations.

Fiscal Third Quarter 2026 Financial Results
Results compare Q3 2026 to the 2025 fiscal third quarter ended August 31, 2025, unless otherwise indicated.

Net revenue for Q3 2026 was $15.3 million, compared to $28.2 million in the fiscal third quarter of 2025 (“Q3 2025”). The approximately 46% year-over-year decrease was driven primarily by a decline in e-commerce sales and slower reorder activity from dealers and chain stores following substantial restocking in fiscal Q1 and slower-than-expected sell-through.

Gross profit for Q3 2026 was $12.2 million (79% of net revenue), down from $16.9 million (60% of net revenue) in Q3 2025. Gross profit for Q3 2026 includes the benefit of a one-time $2.3 million refund of previously paid tariffs. Excluding this item, adjusted gross profit, a non-GAAP measure reconciled below, was $9.9 million, representing adjusted gross margin of approximately 65%, compared to 60% in Q3 2025. The improvement in adjusted gross margin is primarily attributed to improving launcher margins through manufacturing efficiency gains and a continued shift to higher margin products.

Operating expenses for Q3 2026 were $15.1 million, compared to $14.1 million for Q3 2025, an increase of 7%. The increase primarily reflects continued investment in new marketing initiatives as well as $1.7 million in other one-time costs, partially offset by the change in variable selling expenses associated with a decrease in sales.

Net income (loss) for Q3 2026 was $(2.9) million, compared to $2.2 million for Q3 2025. The decline was primarily driven by the factors discussed above, partially offset by lower income tax expense and a net gain in interest and other income.

Adjusted EBITDA1, a non-GAAP metric reconciled below, for Q3 2026 totaled $(1.4) million, compared to $4.1 million in Q3 2025.

Cash, cash equivalents and marketable securities as of August 31, 2026 totaled $9.4 million, compared to $9.0 million at August 31, 2025, and $15.5 million at November 30, 2025. Inventory on August 31, 2026 totaled $30.0 million, compared to $34.1 million at August 31, 2025, and $32.7 million at November 30, 2025. The Company expects inventory levels to continue normalizing in subsequent quarters and more substantially during the upcoming holiday sales period leading to improved working capital efficiency.

Management Commentary
“Over the past several months, we have made significant progress in rebuilding the foundations necessary to support sustainable long-term growth,” said Byrna CEO Conn Davis. “Our results in the quarter reflect our ongoing transition, but we are now starting to see positive signs of new initiatives taking hold and expect to improve sequentially as we approach the end of our fiscal year. For example, we averaged over 29,000 website sessions per day in August, the highest since March of this year. Website conversion also improved from June to August sequentially. Both of these metrics reflect the work we’ve done increasing engagement across our digital channels, onboarding creators to our social engagement program, and launching new media partnerships. While these efforts remain in their early stages, the initial indicators are encouraging and give us confidence that we are moving in the right direction.

“Heading into our critical holiday sales season, we believe we have established a foundation for many of the transformation initiatives and are now focused on executing against them and building momentum. Our refreshed marketing programs are active, our creator network continues to expand, and we are working closely with our expanded dealer base to support holiday sell-through and improve retail productivity. As these initiatives come together, we expect to see more substantial inventory sell through, leading to improved cash generation and overall results. While many of these initiatives remain in their early stages, we are encouraged by the initial results and believe their impact will become more meaningful as they continue to mature and scale.

“Looking further ahead, we believe Byrna’s opportunity extends well beyond current market conditions. By providing consumers with an effective option between being defenseless and carrying a firearm, we are helping reshape the personal safety landscape and expand the less-lethal category. As the clear market leader in the category we pioneered, we believe we are only beginning to unlock the substantial growth opportunity that lies ahead through increased consumer awareness, broader distribution, and continued category adoption.

“Over the next several years, our focus will be on four pillars: continuing to expand awareness, adoption, and distribution of the Byrna brand; extending our presence further into international, professional security, and law enforcement markets; improving operational efficiency through margin expansion, inventory productivity, and cash generation; and evaluating strategic opportunities that strengthen and complement our personal safety platform. Collectively, we believe these initiatives can support a significantly larger, more profitable, and more durable business over time.

“Just as importantly, we now have the team and organizational structure in place to execute against that vision. During the quarter, we strengthened our leadership team with the additions of Jim White and Nate Secor, whose experience in retail growth, omnichannel sales, brand building, and customer acquisition are already helping shape the next phase of Byrna’s evolution. We also enhanced our Board with the appointments of Rose Lopez Keravuori and Dr. Matthew McBrady, adding valuable expertise in governance, risk management, capital allocation, and strategic growth. Collectively, we believe these additions significantly strengthen our ability to execute our strategy and accelerate the development of a larger, more profitable, and more durable business.

“The work underway today is designed not only to improve near-term performance, but to establish a repeatable growth model capable of creating lasting value for our customers, partners, employees, and shareholders over the long term.”

Conference Call
The Company’s management will host a conference call today, October 8, 2026, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) to discuss these results, followed by a question-and-answer period.

Toll-Free Dial-In: 877-709-8150
International Dial-In: +1 201-689-8354
Confirmation: 13762670

Please call the conference telephone number 5-10 minutes prior to the start time of the conference call. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

The conference call will be broadcast live and available for replay here and via the Investor Relations section of Byrna’s website.

About Byrna Technologies Inc.
Byrna is a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company’s investor relations site here. The Company is the manufacturer of the Byrna® CL, Byrna® LE and Byrna® SD personal security devices, state-of-the-art handheld CO2 powered launchers designed to provide a less-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company’s e-commerce store.

Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws. All statements contained in this news release, other than statements of current and historical fact, are forward-looking statements. Often, but not always, forward-looking statements can be identified by the general use of words such as “plans,” “expects,” “intends,” “anticipates,” and “believes” and statements that certain actions, events or results “may,” “could,” “would,” “should,” “might,” “occur,” or “be achieved,” or “will be taken.” Forward-looking statements in this news release include but are not limited to statements concerning expected sequential improvement as Byrna approaches the end of its fiscal year; the anticipated effects of its refreshed marketing programs, creator network, media partnerships, digital engagement efforts and expanded dealer base on brand awareness, customer acquisition, website conversion, holiday sell-through and retail productivity; expected inventory normalization, including during the holiday sales period, and resulting improvements in working capital efficiency and cash generation; the expected effects of outsourced ammunition production and other operational efficiencies on margins, costs and profitability; the anticipated benefits of the HERO Defense Systems, LLC acquisition, including an expanded product portfolio; Byrna’s plans to increase brand awareness and adoption, broaden distribution, extend its presence in international, professional security and law enforcement markets, and evaluate complementary strategic opportunities; and its ability to build a larger, more profitable and durable business over time, as well as statements regarding the growth of the less-lethal personal defense category, Byrna’s market position within that category and the growth opportunity Byrna believes lies ahead, the expected contributions of recently appointed executives and directors, and Byrna’s ability to establish a repeatable growth model and create long-term value for its stakeholders. Forward-looking statements are not, and cannot be, a guarantee of future results or events. Forward-looking statements are based on, among other things, opinions, assumptions, estimates, and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies, and other factors that may cause actual results and events to be materially different from those expressed or implied.

Any number of risk factors could affect our actual results and cause them to differ materially from those expressed or implied by the forward-looking statements in this news release, including, but not limited to, disappointing market responses to current or future products or services; prolonged, new, or exacerbated disruption of our supply chain; the further or prolonged disruption of new product development; production or distribution disruption or delays in entry or penetration of sales channels due to inventory constraints, competitive factors, increased transportation costs or interruptions, including due to weather, flooding or fires; prototype, parts and material shortages, particularly of parts sourced from limited or sole source providers; determinations by third party controlled distribution channels, including Amazon, not to carry or reduce inventory of the Company’s products; determinations by advertisers or social media platforms, or legislation that prevents or limits marketing of some or all Byrna products; the loss of marketing partners; the execution of the Company’s strategic priorities and the integration of recently appointed leaders; the risk that the anticipated benefits of our recently completed acquisition are not realized, or that we are unable to integrate the acquired business on the anticipated timeline or at all; the risk that outsourcing ammunition production increases reliance on third-party suppliers, disrupts supply or does not sustain anticipated margin improvements; the risk that our planned reductions in inventory do not materialize on the anticipated timeline or result in additional inventory write-downs or reserves; investments in e-commerce enhancements or digital capabilities, including improvements to Byrna.com, do not yield anticipated improvements in conversion rates, customer acquisition, or revenue; the risk that efforts to broaden brand messaging or expand into new customer segments do not achieve anticipated market penetration or revenue results; increases in marketing expenditure may not yield expected revenue increases; the risk that creator, media and dealer initiatives do not generate anticipated holiday sell-through, sequential improvement, cash generation or retail productivity; the risk that recent improvements in website traffic and conversion are not sustained; the risk that the Company’s cash resources are insufficient to fund its operations, inventory and strategic initiatives, or that additional financing is not available on acceptable terms or at all; potential cancellations of existing or future orders including as a result of any fulfillment delays, introduction of competing products, negative publicity, or other factors; product design or manufacturing defects or recalls; litigation, enforcement proceedings or other regulatory or legal developments; changes in consumer or political sentiment affecting product demand; regulatory factors including the impact of commerce and trade laws and regulations; changes in domestic or international trade policy, including the imposition of new or increased tariffs, export controls or other trade restrictions, that could result in an increase in the cost of materials, components or finished goods used or sold by the Company, and/ or that could disrupt the Company’s supply chain, or otherwise adversely affect the Company’s costs, revenues, or results of operations; the risk that anticipated manufacturing efficiency improvements do not materialize or are offset by increases in input, labor, or overhead costs; the risk that efforts to expand distribution or develop international, professional security and law enforcement markets are delayed or do not produce anticipated results; and, future restrictions on the Company’s cash resources, increased costs and other events that could potentially reduce demand for the Company’s products or result in order cancellations. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive; accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in the Company’s most recent Form 10-K and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, and should understand it is impossible to predict or identify all such factors or risks, and should not consider the foregoing list, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking information. The Company assumes no obligation to update or revise any forward-looking information, except as required by applicable law.

Investor Contact:
Tom Colton and Greg Bradbury
Gateway Group, Inc.
949-574-3860
BYRN@gateway-grp.com

BYRNA TECHNOLOGIES INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(Amounts in thousands except share and per share data)
(Unaudited)
                   
                   
    For the Three Months Ended   For the Nine Months Ended  
    August 31   August 31  
      2026       2025       2026       2025    
Net revenue   $ 15,296     $ 28,179     $ 60,733     $ 82,874    
Cost of goods sold     3,142       11,257       29,394       32,464    
Gross profit     12,154       16,922       31,339       50,410    
Operating expenses     15,084       14,059       46,186       42,525    
INCOME FROM OPERATIONS     (2,930 )     2,863       (14,847 )     7,885    
OTHER INCOME (EXPENSE)                  
Foreign currency transaction loss     (27 )     (91 )     (224 )     (305 )  
Interest income     37       97       167       400    
Other income     9       (6 )     40       10    
INCOME BEFORE INCOME TAXES     (2,911 )     2,863       (14,864 )     7,990    
Income tax benefit (expense)     –       (628 )     2,666       (1,666 )  
NET INCOME (LOSS)   $ (2,911 )   $ 2,235     $ (12,198 )   $ 6,324    
                   
Foreign currency translation adjustment for the period     29       82       292       27    
Unrealized gain on marketable securities     (14 )     (51 )     (16 )     27    
COMPREHENSIVE INCOME (LOSS)   $ (2,896 )   $ 2,266     $ (11,922 )   $ 6,378    
                   
Basic net income (loss) per share   $ (0.13 )   $ 0.10     $ (0.54 )   $ 0.28    
Diluted net income (loss) per share   $ (0.13 )   $ 0.09     $ (0.54 )   $ 0.26    
                   
Weighted-average number of common shares outstanding – basic     22,981,181       22,691,574       22,779,451       22,649,525    
Weighted-average number of common shares outstanding – diluted     22,981,181       24,103,760       22,779,451       24,147,430    
                   

BYRNA TECHNOLOGIES INC.
Condensed Consolidated Balance Sheets
(Amounts in thousands except share and per share data)
           
           
    August 31   November 30,  
    2026   2025  
    Unaudited      
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents   $ 8,418     $ 13,727    
Marketable Securities     1,001       1,754    
Accounts receivable, net     2,538       10,840    
Inventory, net     29,974       32,694    
Prepaid expenses and other current assets     3,821       4,681    
Total current assets     45,752       63,696    
LONG TERM ASSETS          
Deposits for equipment     245       1,495    
Right-of-use-asset, net     1,051       2,042    
Property and equipment, net     3,869       7,726    
Intangible assets, net     3,944       3,086    
Goodwill     2,714       2,258    
Deferred tax asset     6,855       4,134    
Other assets     153       51    
TOTAL ASSETS   $ 64,583     $ 84,488    
           
LIABILITIES          
CURRENT LIABILITIES          
Accounts payable and accrued liabilities   $ 7,374     $ 15,864    
Operating lease liabilities, current     705       734    
Deferred revenue, current     186       496    
Total current liabilities     8,265       17,094    
LONG TERM LIABILITIES          
Deferred revenue, non-current     18       25    
Operating lease liabilities, non-current     532       1,612    
Contingent consideration liability, non-current     649       –    
Total liabilities     9,464       18,731    
           
           
STOCKHOLDERS‘ EQUITY          
Preferred stock     –       –    
Common stock     25       25    
Additional paid-in capital     138,107       135,870    
Treasury stock     (23,308 )     (22,355 )  
Accumulated deficit     (59,294 )     (47,096 )  
Accumulated other comprehensive loss     (411 )     (687 )  
           
Total Stockholders’ Equity     55,119       65,757    
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 64,583     $ 84,488    
           

Non-GAAP Financial Measures

In addition to providing financial measurements based on generally accepted accounting principles in the United States (GAAP), we provide additional financial measures that are not prepared in accordance with GAAP (non-GAAP), consisting of non-GAAP adjusted EBITDA, non-GAAP adjusted cost of goods sold and non-GAAP adjusted gross profit (and the related adjusted gross profit margin). Management uses these non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. We believe that this non-GAAP financial measure helps us to identify underlying trends in our business that could otherwise be masked by the effect of certain expenses that we exclude in the calculations of the non-GAAP financial measure.

Accordingly, we believe that this non-GAAP financial measure reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business and provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.

This non-GAAP financial measure does not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. There are limitations in the use of non-GAAP measures, because they do not include all the expenses that must be included under GAAP and because they involve the exercise of judgment concerning exclusions of items from the comparable non-GAAP financial measure. In addition, other companies may use other non-GAAP measures to evaluate their performance, or may calculate non-GAAP measures differently, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison.

Adjusted EBITDA 

Adjusted EBITDA is defined as net (loss) income as reported in our condensed consolidated statements of operations and comprehensive (loss) income excluding the impact of (i) depreciation and amortization; (ii) income tax provision (benefit); (iii) interest income (expense); (iv) stock-based compensation expense, (v) impairment loss, and (vi) one time, non-recurring other expenses or income. Our Adjusted EBITDA measure eliminates potential differences in performance caused by variations in capital structures (affecting finance costs), tax positions, the cost and age of tangible assets (affecting relative depreciation expense) and the extent to which intangible assets are identifiable (affecting relative amortization expense). We also exclude certain one-time and non-cash costs. Reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP measure, is as follows (in thousands):

                     
                     
      For the Three Months Ended   For the Nine Months Ended  
      August 31   August 31  
        2026       2025       2026       2025    
Net Income (Loss)   $ (2,911 )   $ 2,235     $ (12,198 )   $ 6,324    
                     
Adjustments:                  
  Interest income     (37 )     (97 )     (167 )     (400 )  
  Income tax expense     –       628       (2,666 )     1,666    
  Depreciation and amortization     466       618       1,828       1,617    
Non-GAAP EBITDA   $ (2,482 )   $ 3,384     $ (13,203 )   $ 9,207    
                     
Stock-based compensation expense     601       734       1,972       2,297    
Impairment loss     –       –       4,506       –    
Write-down of ammunition inventory     –       –       3,605       –    
Inventory reserve – strategic product rationalization     –       –       2,324       –    
Severance/Leadership transition     521       (36 )     1,041       210    
Non-GAAP adjusted EBITDA   $ (1,360 )   $ 4,082     $ 245     $ 11,714    
                     

Adjusted Cost of goods sold and gross profit

Adjusted cost of goods sold is defined as cost of goods sold as reported in our condensed consolidated statements of operations and comprehensive (loss) income excluding the impact of (i) impairment loss; (ii) write down of ammunition inventory; (iii) inventory reserve due to strategic product rationalization, and (iv) refunds of previously paid tariffs. Our Adjusted cost of goods sold measure eliminates potential differences in performance caused by certain one-time or unusual events. Adjusted gross profit is defined as revenue as reported in our condensed consolidated statement of operations and comprehensive (loss) income less Adjusted cost of goods sold. Reconciliation of Adjusted cost of goods sold to Cost of goods sold, as well as a reconciliation of Adjusted Gross profit to Gross profit, the most directly comparable GAAP measures, are as follows (in thousands):

                   
                   
    For the Three Months Ended   For the Nine Months Ended  
    August 31   August 31  
      2026       2025       2026       2025    
Net revenue $ 15,296     $ 28,179     $ 60,733     $ 82,874    
Cost of goods sold   3,142       11,257       29,394       32,464    
Gross profit   12,154       16,922       31,339       50,410    
Gross profit margin   79.5 %     60.1 %     51.6 %     60.8 %  
                   
Cost of goods sold   3,142       11,257       29,394       32,464    
Adjustments:                
  Impairment loss   –       –       (3,488 )     –    
  Tariff refund   2,282       –       3,349       –    
  Write-down of ammunition inventory   –       –       (3,605 )     –    
  Inventory reserve – strategic product rationalization   –       –       (2,324 )     –    
Non-GAAP adjusted cost of goods sold   5,424       11,257       23,326       32,464    
                   
Non-GAAP adjusted gross profit   9,872       16,922       37,407       50,410    
Non-GAAP adjusted gross profit margin   64.5 %     60.1 %     61.6 %     60.8 %  
                   

________________
1
See non-GAAP financial measures at the end of this press release for a reconciliation and a discussion of non-GAAP financial measures.

Using multiple vendors across Kratos’ OpenSpace’s fully virtualized platform proves that space can support terrestrial-level interoperability and scale

SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company specializing in defense, national security, and global markets, today announced that it has successfully demonstrated end-to-end connectivity across a native, multi-vendor 5G NR NTN (New Radio Non-Terrestrial Network) using Kratos’ OpenSpace®, the industry’s first fully virtualized and software-defined satellite ground system platform. This demonstration showcased the benefits of virtualization in supporting the level of interoperability and scale necessary for satellite operators to provide seamless 5G services.

A virtualized ground system offers the most advantageous path forward for operators seeking flexibility and scalability. OpenSpace’s software-defined architecture allows satellite systems to behave more like terrestrial 5G infrastructure, enabling operators to dynamically scale services, reduce hardware dependencies and adopt multi‑vendor solutions that best support mission, performance and cost requirements. Multi-vendor support gives operators the ability to choose the best software for a service and the best cost-performance option for a given beam or region and more.

In this demonstration with Korea-based satellite operator KT SAT and other partners, Kratos proved connectivity across a native 5G NR Non-Terrestrial Network consisting of an OpenSpace RAN (Radio Access Network), Druid Software’s Raemis 5G Core and GCT Semiconductor Holding’s (NYSE: GCTS) GDM7275X-based 5G UE (User Equipment). This integrated system performed cell search and successfully registered with the Druid Raemis core to establish two-way communication and validate multi-vendor interoperability.

“KT SAT is committed to advancing 5G NTN solutions in the satellite industry,” said Sungho Choi, KT SAT CTO. “By bringing partners together and supporting this demonstration, we’re accelerating the ecosystem and proving that interoperable, multi‑vendor 5G systems are not just theoretical, they are happening now.”

“Our goal with OpenSpace has always been to give satellite operators the flexibility and interoperability that 5G promises,” said Jennifer Barber, Senior Director of Product Management 5G NTN Solutions at Kratos. “This collaboration is an important step toward open, multi‑vendor 5G NTN deployments. We’re pleased to work with KT SAT and our partners in driving 5G development forward in the industry.”

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:

877-934-4687
investor@kratosdefense.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.